PAREXEL Academy Adds Programs for Students
Three new academic programs have been added to the PAREXEL Academy which span the globe and are designed to prepare students for careers in the biopharmaceutical industry.
Three new academic programs have been added to the PAREXEL Academy which span the globe and are designed to prepare students for careers in the biopharmaceutical industry:
·Bachelor of Science Degree in Clinical Research – Offered in partnership with the Medical School Berlin, in Berlin, Germany, the degree program features courses specific to clinical research. Courses range from ethics in health and medicine to conducting clinical trials. Several courses are taught by PAREXEL experts.
·Postgraduate Certificate in Clinical Trial Management – In cooperation with Salem State University in Salem, Massachusetts, the postgraduate certificate program features a broad-based curriculum in various components of the full life cycle of drug development.
·Joint Program for Clinical Research and Clinical Trial Management – In collaboration with Kyoto Pharmaceutical University in Kyoto, Japan, the joint program provides fifth grade undergraduate students an introductory, seven-week course in clinical research and clinical trial management.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Oveporexton Shows Superior Efficacy in Phase II Narcolepsy Type 1 Trial Without Hepatotoxicity
May 16th 2025In the TAK-861-2001 Phase IIb study, oveporexton significantly improved wakefulness, daytime sleepiness, and cataplexy frequency in patients with narcolepsy type 1, outperforming current therapies and avoiding liver toxicity seen with earlier OX2R agonists, according to results published in The New England Journal of Medicine.
